Oramed Pharmaceuticals Inc. (ORMP)
Company Description
Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules for delivery of polypeptides.
The company's product portfolio includes ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes, as well as in phase II clinical trial for the treatment of non-alcoholic steatohepatitis; and ORA-D-013-1 and ORA-D-013-2, which have completed phase II clinical trial for the treatment of type 2 diabetes.
It has license agreements with Oravax Medical Inc. to commercialize oral vaccines for COVID-19 and other novel coronaviruses.
Oramed Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in New York.
Country | United States |
Founded | 2002 |
Industry | Biotechnology |
Sector | Healthcare |
Employees | 13 |
CEO | Nadav Kidron Esq. |
Contact Details
Address: 1185 Avenue Of The Americas, 3rd Floor New York, New York 10036 United States | |
Phone | 646-844-1164 |
Website | oramed.com |
Stock Details
Ticker Symbol | ORMP |
Exchange | NASDAQ |
Fiscal Year | January - December |
Reporting Currency | USD |
CIK Code | 0001176309 |
CUSIP Number | 68403P203 |
ISIN Number | US68403P2039 |
Employer ID | 98-0376008 |
SIC Code | 2834 |
Key Executives
Name | Position |
---|---|
Nadav Kidron Esq. | President, Chief Executive Officer and Executive Chairman |
David Silberman CPA | Chief Financial Officer and Treasurer |
Dr. Miriam Kidron Ph.D. | Chief Scientific Officer and Director |
Joshua Hexter | Chief Operating and Business Officer |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Mar 22, 2024 | SC 13D | General statement of acquisition of beneficial ownership |
Mar 19, 2024 | 8-K | Current Report |
Mar 18, 2024 | 8-K | Current Report |
Mar 18, 2024 | 8-K | Current Report |
Mar 18, 2024 | 424B5 | Filing |
Mar 6, 2024 | 10-K | Annual Report |
Feb 20, 2024 | 8-K | Current Report |
Jan 23, 2024 | 8-K | Current Report |
Jan 19, 2024 | 8-K | Current Report |
Dec 21, 2023 | 8-K | Current Report |